Drug Trial Radar · NCT06095505
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Feb 8, 2024
Primary completion
Oct 30, 2027
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- Puma Biotechnology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1/PD-1 immunotherapy agent. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior treatment regimens. This study is intended to identify the biomarker-defined subgroup(s) that may benefit most from alisertib treatment and to evaluate the efficacy, safety, and pharmacokinetics of alisertib.
Conditions
- Small Cell Lung Cancer
Interventions
AlisertibDrug
Alisertib enteric-coated tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR) within biomarker-defined subgroupTime frame: From date of first dose to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 36 months
- Duration of response (DOR) within biomarker-defined subgroupTime frame: From start date of response (after date of first dose) to first PD, assessed up to 36 months
- Disease Control Rate (DCR) within biomarker-defined subgroupTime frame: From date of first dose to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 36 months
- Progression Free Survival (PFS) within biomarker-defined subgroupTime frame: From date of first dose to date of recurrence, progression or death, assessed up to 36 months
- Overall Survival (OS) within biomarker-defined subgroupTime frame: From date of first dose to death, assessed up to 36 months
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
Southern Cancer Center
Daphne, Alabama · Recruiting
The Oncology Institute of Hope and Innovation
Long Beach, California · Recruiting
Rocky Mountain Cancer Centers
Lone Tree, Colorado · Recruiting
Georgetown Lombardi Cancer Center
Washington D.C., District of Columbia · Recruiting
Clermont Oncology Center
Clermont, Florida · Recruiting
The Oncology Institute of Hope and Innovation
Fort Lauderdale, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Illinois Cancer Specialists
Niles, Illinois · Recruiting
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana · Recruiting
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Henry Ford Hospital
Detroit, Michigan · Completed
Minnesota Oncology Hematology
Burnsville, Minnesota · Recruiting
Nebraska Cancer Specialists
Grand Island, Nebraska · Recruiting
Oncology Hematology Care Clinical Trials
Cincinnati, Ohio · Recruiting
University Hospital - Cleveland Medical Center
Cleveland, Ohio · Recruiting
Cleveland Clinic
Cleveland, Ohio · Active not recruiting
Zangmeister Cancer Center
Columbus, Ohio · Recruiting
Oncology Associates of Oregon
Eugene, Oregon · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Withdrawn
Medical University of South Carolina Hollings Cancer Center
Charleston, South Carolina · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas · Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas · Recruiting
Oncology & Hematology Associates of Southwest Virginia
Blacksburg, Virginia · Recruiting
Universtity of Virginia Health System
Charlottesville, Virginia · Completed
Virginia Cancer Specialists Research Institute
Fairfax, Virginia · Recruiting
Northwest Cancer Specialists
Vancouver, Washington · Recruiting
Marshfield Medical Center
Marshfield, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.